Telix Pharmaceuticals (TLX.AX) Stock Price

Telix Pharmaceuticals Price

Delisted·Jun 19, 2026
10.11USD-0.06 (-0.54 %)
Last traded price

Revenue has compounded at 228.4% per year over the past 7 years to 803.79 M USD. Telix Pharmaceuticals's net margin stands at -0.9%, up from -1,059.9% several years earlier. Analysts set a median price target of 16.29 USD, implying 61.1% above the current price. Of 17 analysts, 16 rate the stock a buy — an overall Buy consensus. The stock trades about 62% above its 52-week low.

Telix Pharmaceuticals stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Telix Pharmaceuticals over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Telix Pharmaceuticals stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Telix Pharmaceuticals's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Telix Pharmaceuticals Stock Price History
DateTelix Pharmaceuticals Price
6/19/202610.11 USD
6/18/202610.17 USD
6/17/202610.09 USD
6/16/20269.60 USD
6/15/20269.86 USD
6/12/20269.71 USD
6/11/20269.36 USD
6/10/20269.58 USD
6/9/20269.49 USD
6/5/20269.77 USD
6/4/20269.14 USD
6/3/20268.74 USD
6/2/20269.07 USD
6/1/20269.46 USD
5/29/20269.33 USD
5/28/20269.48 USD
5/27/20269.80 USD
5/26/20269.22 USD
5/25/20269.91 USD
5/22/20269.55 USD
5/21/202610.16 USD
5/20/202610.21 USD
5/19/202610.30 USD
5/18/202610.34 USD
5/15/202610.67 USD
5/14/202610.77 USD
5/13/202610.53 USD
5/12/202610.46 USD
5/11/202610.84 USD
5/8/202610.69 USD
5/7/202610.94 USD
5/6/202611.03 USD
5/5/202611.19 USD
5/4/202611.31 USD
5/1/202611.29 USD
4/30/202610.88 USD
4/29/202610.88 USD
4/28/202610.69 USD
4/27/202610.65 USD
4/24/202610.80 USD
4/23/202610.46 USD
4/22/202610.38 USD
4/21/202610.50 USD
4/20/202610.70 USD
4/17/202610.61 USD
4/16/202610.88 USD
4/15/202610.73 USD
4/14/202611.20 USD
4/13/202611.43 USD
4/10/202610.61 USD
4/9/20269.89 USD
4/8/202610.11 USD
4/7/20269.85 USD
4/2/20269.39 USD
4/1/20269.57 USD
3/31/20269.90 USD
3/30/20269.45 USD
3/27/20269.90 USD
3/26/20269.37 USD
3/25/20269.23 USD
3/24/20269.06 USD
3/23/20269.28 USD
3/20/20269.24 USD
3/19/20269.00 USD
3/18/20268.98 USD
3/17/20268.48 USD
3/16/20267.96 USD
3/13/20268.19 USD
3/12/20268.14 USD
3/11/20267.80 USD
3/10/20267.98 USD
3/9/20267.40 USD
3/6/20267.79 USD
3/5/20267.32 USD
3/4/20266.87 USD
3/3/20267.16 USD
3/2/20267.08 USD
2/27/20267.25 USD
2/26/20267.40 USD
2/25/20266.67 USD
2/24/20266.55 USD
2/23/20266.97 USD
2/20/20267.56 USD
2/19/20266.62 USD
2/18/20266.44 USD
2/17/20266.41 USD
2/16/20266.26 USD
2/13/20266.35 USD
2/12/20266.58 USD
2/11/20267.07 USD
2/10/20267.29 USD
2/9/20267.15 USD
2/6/20267.14 USD
2/5/20267.34 USD
2/4/20267.34 USD
2/3/20267.40 USD
2/2/20267.60 USD
1/30/20267.65 USD
1/29/20268.03 USD
1/28/20268.45 USD
1/27/20268.60 USD
1/23/20267.94 USD
1/22/20267.92 USD
1/21/20267.69 USD
1/20/20268.33 USD
1/19/20268.18 USD
1/16/20268.32 USD
1/15/20268.08 USD
1/14/20268.05 USD
1/13/20267.98 USD
1/12/20268.12 USD
1/9/20268.15 USD
1/8/20268.21 USD
1/7/20267.98 USD
1/6/20267.95 USD
1/5/20268.16 USD
1/2/20268.24 USD
12/31/20258.12 USD
12/30/20258.42 USD
12/29/20258.53 USD
12/24/20258.62 USD
12/23/20258.66 USD
12/22/20258.64 USD
12/19/20258.58 USD
12/18/20258.57 USD
12/17/20258.50 USD
12/16/20259.11 USD
12/15/20259.55 USD
12/12/20259.96 USD
12/11/20259.93 USD
12/10/202510.15 USD
12/9/202510.38 USD
12/8/202510.58 USD
12/5/202510.74 USD
12/4/202510.56 USD
12/3/202510.35 USD
12/2/202510.48 USD
12/1/202510.91 USD
11/28/202511.04 USD
11/27/202511.09 USD
11/26/202510.90 USD
11/25/202510.77 USD
11/24/202510.11 USD
11/21/20259.99 USD
11/20/202510.06 USD
11/19/202510.11 USD
11/18/202510.19 USD
11/17/202510.30 USD
11/14/202510.24 USD
11/13/202510.86 USD
11/12/202510.82 USD
11/11/202511.33 USD
11/10/202511.11 USD
11/7/202510.88 USD
11/6/202510.99 USD
11/5/202511.28 USD
11/4/202511.42 USD
11/3/202511.46 USD
10/31/202511.66 USD
10/30/202511.73 USD
10/29/202511.72 USD
10/28/202511.91 USD
10/27/202512.09 USD
10/24/202511.98 USD
10/23/202512.18 USD
10/22/202512.19 USD
10/21/202512.29 USD
10/20/202511.96 USD
10/17/202512.07 USD
10/16/202512.28 USD
10/15/202512.11 USD
10/14/202510.41 USD
10/13/202510.50 USD
10/10/202510.96 USD
10/9/202511.17 USD
10/8/202511.17 USD
10/7/202511.00 USD
10/6/202511.10 USD
10/3/202511.16 USD
10/2/202511.15 USD
10/1/202511.02 USD
9/30/202510.56 USD
9/29/202510.92 USD
9/26/202510.77 USD
9/25/202511.15 USD
9/24/202511.21 USD
9/23/202511.88 USD
9/22/202510.88 USD
9/19/202510.53 USD
9/18/20259.90 USD
9/17/202510.09 USD
9/16/202510.22 USD
9/15/202510.15 USD
9/12/20259.93 USD
9/11/20259.99 USD
9/10/202510.46 USD
9/9/202510.02 USD
9/8/20259.86 USD
9/5/202510.01 USD
9/4/20259.98 USD
9/3/202510.26 USD
9/2/202510.38 USD
9/1/202510.80 USD
8/29/202510.59 USD
8/28/202510.84 USD
8/27/202513.34 USD
8/26/202513.72 USD
8/25/202513.60 USD
8/22/202513.29 USD
8/21/202513.12 USD
8/20/202512.27 USD
8/19/202512.71 USD
8/18/202512.86 USD
8/15/202512.69 USD
8/14/202512.34 USD
8/13/202512.42 USD
8/12/202512.09 USD
8/11/202512.25 USD
Access this data via the Eulerpool API
Get Free API Key

Telix Pharmaceuticals Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
332.98 M USD
12.29 M USD
4.21 M USD
Jan 1, 2024
516.55 M USD
54.58 M USD
33.69 M USD
Jan 1, 2025
803.79 M USD
30.91 M USD
-7.13 M USD
Jan 1, 2026 (e)
984.98 M USD
-286.54 M USD
12.84 M USD
Jan 1, 2027 (e)
1.14 B USD
-331.55 M USD
30.43 M USD
Jan 1, 2028 (e)
1.33 B USD
-387.67 M USD
87.24 M USD
Jan 1, 2029 (e)
1.44 B USD
-420.15 M USD
169.38 M USD
Jan 1, 2030 (e)
1.66 B USD
-483.95 M USD
267.86 M USD

Telix Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 8, 2026, 2:54 PM
 
REVENUEB USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
2017201820192020202120222023202420252026e2027e2028e2029e2030e2031e
–––0.010.010.100.330.520.800.981.141.331.441.662.15
–––66.6740.001,371.43222.3355.4255.6222.5415.7516.948.4115.1729.34
––12,700.0060.0071.4359.2261.1461.8247.4547.4547.4547.4547.4547.4547.45
0.380.380.38–0.010.060.200.320.380.470.540.630.690.791.02
-6.00-17.00-28.00-35.00-76.00-58.0012.0054.0030.00-286.00-331.00-387.00-420.00-483.00–
––-933.33-700.00-1,085.71-56.313.6110.473.74-29.07-29.06-29.05-29.09-29.04–
-6.00-13.00-27.00-44.00-80.00-67.004.0033.00-7.0012.0030.0087.00169.00267.00263.00
–116.67107.6962.9681.82-16.25-105.97725.00-121.21-271.43150.00190.0094.2557.99-1.50
127.99202.12233.44257.27282.21310.64323.71345.19337.88337.88337.88337.88337.88337.88337.88
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Telix Pharmaceuticals generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Telix Pharmaceuticals retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Telix Pharmaceuticals's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Telix Pharmaceuticals has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Telix Pharmaceuticals's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Telix Pharmaceuticals stock margins

The Telix Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Telix Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Telix Pharmaceuticals.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
66.46 %
-1,012.97 %
-1,059.90 %
Jan 1, 2022
59.29 %
-56.72 %
-65.01 %
Jan 1, 2023
61.05 %
3.69 %
1.26 %
Jan 1, 2024
61.85 %
10.57 %
6.52 %
Jan 1, 2025
47.51 %
3.84 %
-0.89 %
Jan 1, 2026 (e)
47.51 %
-29.09 %
1.30 %
Jan 1, 2027 (e)
47.51 %
-29.09 %
2.67 %
Jan 1, 2028 (e)
47.51 %
-29.09 %
6.55 %

Telix Pharmaceuticals Stock Revenue, EBIT, Earnings per Share

The Telix Pharmaceuticals earnings per share therefore indicates how much revenue Telix Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.03 USD
-0.27 USD
-0.29 USD
Jan 1, 2022
0.33 USD
-0.19 USD
-0.22 USD
Jan 1, 2023
1.03 USD
0.04 USD
0.01 USD
Jan 1, 2024
1.50 USD
0.16 USD
0.10 USD
Jan 1, 2025
2.38 USD
0.09 USD
-0.02 USD
Jan 1, 2026 (e)
2.92 USD
-0.85 USD
0.04 USD
Jan 1, 2027 (e)
3.37 USD
-0.98 USD
0.09 USD
Jan 1, 2028 (e)
3.94 USD
-1.15 USD
0.26 USD

Telix Pharmaceuticals business model & stock analysis

Telix Pharmaceuticals Ltd. is a leading biopharmaceutical company specializing in the development of diagnostic and therapeutic solutions that work at the molecular level. The company's activities span across Europe, North America, and the Asia-Pacific region. Telix was formed through the merger of two Australian companies - Advanced Nuclear Medicine Ingredients (ANMI) and Radiopharmaceuticals Pty Ltd. The company's business model is based on translational medicine and it works closely with academic research groups and international partners to develop products and technologies aligned with the latest medical research and scientific knowledge. Telix has two main business divisions: Imaging and Therapy. The Imaging division focuses on the development of diagnostic radiopharmaceuticals for cancer and inflammation imaging, while the Therapy division concentrates on the development of radiopharmaceuticals for the treatment of cancer and other chronic diseases. The company offers a wide portfolio of products and solutions tailored to diseases of the nervous and immune systems, as well as to cancer diagnosis and treatment. These include the Prostate-Specific Membrane Antigen (PSMA)-targeting technology, which has the potential to significantly improve the early diagnosis and progression of prostate cancer, radiopharmaceuticals for bone imaging to enhance the diagnosis of bone metastases and other bone diseases, and radiopharmaceuticals for cancer therapy that show promising results in precision tumor treatment. Telix Pharmaceuticals aims to improve the diagnosis, treatment, and quality of life for patients with chronic diseases through its innovative products, strong network of partners, and commitment to entrepreneurial excellence.

Telix Pharmaceuticals SWOT Analysis

Strengths

Telix Pharmaceuticals Ltd has a strong portfolio of innovative and advanced radiopharmaceutical products.

The company has established strategic partnerships with leading healthcare organizations, which enhances its market presence.

Telix Pharmaceuticals Ltd has a highly skilled workforce with deep expertise in radiopharmaceutical development and commercialization.

Weaknesses

The company is heavily dependent on the success of its research and development efforts, which may lead to unpredictable outcomes.

Telix Pharmaceuticals Ltd faces certain regulatory and compliance challenges in different markets, potentially affecting its growth prospects.

Limited financial resources may restrict the company's ability to expand and invest in new projects.

Opportunities

The global radiopharmaceutical market is expected to witness significant growth, providing Telix Pharmaceuticals Ltd with opportunities to expand its market share.

Advancements in technology and increasing adoption of targeted molecular imaging offer Telix Pharmaceuticals Ltd chances to develop innovative radiopharmaceutical products.

Growing awareness of personalized medicine and the potential benefits of radiopharmaceuticals present opportunities for Telix Pharmaceuticals Ltd to capitalize on.

Threats

Competition from established pharmaceutical companies and emerging startups pose threats to Telix Pharmaceuticals Ltd's market position.

Stringent regulations and reimbursement policies in the healthcare industry may impact the pricing and availability of radiopharmaceutical products, affecting the company's profitability.

The ongoing COVID-19 pandemic has disrupted healthcare systems worldwide, which could cause delays in clinical trials or market launches of Telix Pharmaceuticals Ltd's products.

Telix Pharmaceuticals Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Telix Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio

Telix Pharmaceuticals annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Telix Pharmaceuticals shares outstanding

The number of shares of Telix Pharmaceuticals was 337.88 M in 2025. This indicates how many shares Telix Pharmaceuticals is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
282.21 M Stocks
Jan 1, 2022
310.64 M Stocks
Jan 1, 2023
323.71 M Stocks
Jan 1, 2024
345.19 M Stocks
Jan 1, 2025
337.88 M Stocks
Jan 1, 2026 (e)
337.88 M Stocks
Jan 1, 2027 (e)
337.88 M Stocks
Jan 1, 2028 (e)
337.88 M Stocks

Current Telix Pharmaceuticals forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
94.12 % (16)
Hold
5.88 % (1)
Sell
0.00 % (0)
12M Price Target
0.00
Last Price
10.11
Currency
USD
12M Return Potential
-100.00 %
LTM Return
0 %

Telix Pharmaceuticals Earnings Calls

Telix Pharmaceuticals Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
2/18/20240.05USD-282.52 MUSD-2023 Q4
8/16/20230.01USD-131.85 MUSD-2023 Q2
2/22/2023-0.02USD-128.43 MUSD-2022 Q4
8/18/2022-0.11USD-27.95 MUSD-2022 Q2
1/24/2022-0.08USD-3.45 MUSD-2021 Q4
8/19/2021-0.10USD-4.62 MUSD-2021 Q2

EESG©

Eulerpool ESG Scorecard© for the Telix Pharmaceuticals stock

65/100
34
Environment
93
Social
69
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees51
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Telix Pharmaceuticals shareholder structure

% Name
6.71096%
Gnosis Verwaltungsgesellschaft mbH
Gnosis Verwaltungsgesellschaft mbH
6.31260%
Behrenbruch (Christian P. Ph.D.)
Behrenbruch (Christian P. Ph.D.)
4.80187%
Challenger Ltd
Challenger Ltd
4.35089%
State Street Investment Management Australia Ltd.
State Street Investment Management Australia Ltd.
2.26647%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
1.89486%
Norges Bank Investment Management (NBIM)
Norges Bank Investment Management (NBIM)
...

Telix Pharmaceuticals Beneficial Ownership Filings (SEC 13D/G)

Free Float
81.5%
Float Shares
-
Shares Outstanding
-

Telix Pharmaceuticals Executives and Management Board

15 members · avg. age 67 · 33 % women

CB

Dr. Christian Behrenbruch

Group Chief Executive Officer, Managing Director, Executive Director · since 2017

1.41 M USD

Management

DS

Mr. Darren Smith

Group Chief Financial Officer

1.22 M USD
DC

Dr. David Cade

Group Chief Medical Officer · since 2024

1.07 M USD
RV

Mr. Richard Valeix

Group Chief Commercial Officer

1.01 M USD
DP

Dr. Darren Patti

Group Chief Operating Officer

930,735.00 USD
RO

Mr. Raphaeel Ortiz

Chief Executive Officer - Telix International

–
KR

Mr. Kevin Richardson

Chief Executive Officer - Telix Precision Medicine

–

Board of Directors

TO

Ms. Tiffany Olson (65)

Non-Executive Independent Chairman of the Board

203,568.00 USD
JS

Ms. Jann Skinner

Non-Executive Independent Director

155,000.00 USD
MN

Dr. Mark Nelson

Non-Executive Independent Director

135,000.00 USD
MM

Ms. Marie McDonald (69)

Non-Executive Director

–

Telix Pharmaceuticals Supply Chain

Telix Pharmaceuticals Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
10 companies
#NameTrend
1
Merck
Supplier·Customer·Pharmaceuticals·DE
0.75
0.42
-0.03
0.64
0.66
0.91
2
JPMorgan Chase
Supplier·Customer·Banks·US
-0.18
0.43
0.81
0.82
0.49
0.86
3
Eckert & Ziegler Strahlen
Supplier·Customer·Health Care Equipment & Supplies·DE
0.81
0.62
0.79
0.79
0.34
0.77
4
HSBC Holdings
Supplier·Customer·Banks·GB
0.23
0.47
0.56
-0.36
-0.15
0.61
5
Heidelb Ph
Supplier·Customer·Biotechnology·DE
0.66
0.26
-0.68
-0.29
-0.27
0.34
#NameTrend
1
Yantai Dongcheng Biochems A
Supplier·Customer·Biotechnology·CN
0.38
0.49
0.65
0.80
0.06
-0.61
2
Amgen
Customer·Biotechnology·US
0.34
0.57
-0.58
-0.55
-0.51
-0.51
3
Mauna Kea Technologies O
Supplier·Customer·Health Care Equipment & Supplies·FR
0.68
0.33
0.09
0.60
0
-0.44
4
Grand Pharmaceutical Group
Supplier·Customer·Pharmaceuticals·HK
0.66
0.52
0.51
0.70
0.10
-0.10
5
Cardinal Health
Customer·Health Care Providers & Services·US
0.05
0.48
-0.59
-0.72
-0.62
-0.01

Frequently asked questions about Telix Pharmaceuticals

The business model of Telix Pharmaceuticals Ltd revolves around the development and commercialization of molecularly targeted radiation (MTR) products. As a leading biopharmaceutical company, Telix focuses on producing innovative diagnostic and therapeutic solutions for patients suffering from cancer. By utilizing its expertise in radiopharmaceuticals and molecular targeting, Telix aims to enhance the precision and efficacy of cancer diagnosis, imaging, and treatment. Through collaborations with various partners, Telix strives to bring advanced diagnostic imaging technologies and personalized treatment options to healthcare professionals and patients worldwide. Telix Pharmaceuticals Ltd plays a crucial role in improving patient outcomes and advancing the field of nuclear medicine.

Telix Pharmaceuticals Ltd is primarily active in the pharmaceutical and biotechnology industries.

The main competitors of Telix Pharmaceuticals Ltd in the market are other pharmaceutical companies operating in the same sector, focusing on molecularly targeted radiation (MTR) therapies and diagnostic imaging products for oncology. These competitors include established players such as Advanced Accelerator Applications SA (a Novartis company), Bayer AG, Curium Pharmaceuticals, and Progenics Pharmaceuticals. Telix Pharmaceuticals Ltd distinguishes itself through its innovative radiopharmaceutical solutions, strategic collaborations, and ongoing clinical trials.

Telix Pharmaceuticals Ltd is an innovative biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for cancer diagnosis and treatment. Established in 2016, Telix has rapidly grown into a global player in the molecularly targeted radiation therapy field. The company has successfully acquired and developed a diverse portfolio of diagnostic and therapeutic products, leveraging its cutting-edge technology and strategic partnerships. Telix has made significant progress in clinical trials, regulatory approvals, and commercialization efforts, demonstrating its commitment to improving patient outcomes in oncology. With its dedicated team and robust pipeline, Telix Pharmaceuticals Ltd is poised to revolutionize cancer management through personalized and targeted radiopharmaceuticals.

Telix Pharmaceuticals Ltd has achieved several significant milestones. Firstly, the company successfully completed its Phase III clinical trial for TLX591-CDx, a prostate cancer imaging agent. Additionally, Telix Pharmaceuticals received regulatory approval in the United States, Europe, and Canada for TLX591-CDx, allowing for its commercialization. Another notable achievement is the successful completion of a collaboration agreement with China Grand Pharma, expanding Telix's presence in the Chinese market. Furthermore, Telix Pharmaceuticals entered into a licensing agreement with ANMI SA, enhancing its product portfolio for molecular imaging. These achievements highlight Telix Pharmaceuticals' commitment to developing innovative solutions in the field of radiopharmaceuticals.

Telix Pharmaceuticals Ltd primarily operates in several countries and regions, including Australia, the United States, Europe, and Japan.

Telix Pharmaceuticals Ltd represents a strong commitment to improving the diagnosis and treatment of cancer. With a focus on molecularly targeted radiation therapy, the company aims to develop innovative radiopharmaceuticals that can deliver more precise and effective cancer treatments. Telix Pharmaceuticals embraces a patient-centered approach, continually striving to enhance patient outcomes and improve quality of life. The company is dedicated to fostering collaborations, driving scientific advancements, and delivering transformative therapies to individuals battling cancer. Telix Pharmaceuticals Ltd stands as a beacon of innovation, aiming to revolutionize the field of cancer medicine with its cutting-edge technologies and unwavering dedication to making a difference.

Analysts currently set an average price target of 17.10 USD for the Telix Pharmaceuticals stock (median: 16.29 USD), implying +69.1 % versus the latest price. The consensus is based on 17 analyst ratings.

Telix Pharmaceuticals Analyst Price Targets 2026

17 analysts currently rate the Telix Pharmaceuticals stock: 16 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Telix Pharmaceuticals to generate revenue of 984.98 M USD and earnings per share of 0.04 USD.

Telix Pharmaceuticals Analyst Price Targets 2026

Converted at the current exchange rate, the Telix Pharmaceuticals share trades at 8.75 EUR (10.11 USD).

The Telix Pharmaceuticals share (TLX.AX) is listed on 2 stock exchanges, including: ASX (TLX.AX).

Telix Pharmaceuticals Ltd is an Australian biotechnology company specializing in the development and commercialization of diagnostic technologies and therapeutic products for oncology.

The expected revenue of Telix Pharmaceuticals is 984.98 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Telix Pharmaceuticals is 12.84 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Telix Pharmaceuticals is currently 266.19. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Telix Pharmaceuticals stock.

The price-to-sales ratio (P/S) of Telix Pharmaceuticals is currently 3.47. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Telix Pharmaceuticals stock.

The Eulerpool Quality Score for Telix Pharmaceuticals is 3/10.

The ISIN of Telix Pharmaceuticals is AU000000TLX2. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Telix Pharmaceuticals is A2H7JK. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Telix Pharmaceuticals is TLX.AX. The ticker symbol is used to trade Telix Pharmaceuticals shares on the stock exchange.

Telix Pharmaceuticals paid dividends every year for the past 0 years.

Telix Pharmaceuticals is assigned to the 'Health' sector.

The dividends of Telix Pharmaceuticals are distributed in USD.

All fundamentals and in-depth analysis of Telix Pharmaceuticals

Our stock analysis for Telix Pharmaceuticals stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Telix Pharmaceuticals. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Telix Pharmaceuticals Stock
Telix Pharmaceuticals Revenue→
Telix Pharmaceuticals Stock
Telix Pharmaceuticals Net Income→
Telix Pharmaceuticals Stock
Telix Pharmaceuticals P/E→
Telix Pharmaceuticals Stock
Telix Pharmaceuticals P/S→
Telix Pharmaceuticals Stock
Telix Pharmaceuticals EBIT→
Telix Pharmaceuticals Stock
Telix Pharmaceuticals Dividend→
Telix Pharmaceuticals Stock
Telix Pharmaceuticals Directors Dealings→
Telix Pharmaceuticals Stock
Telix Pharmaceuticals Stocks→
Telix Pharmaceuticals Stock
Telix Pharmaceuticals Market capitalization→
Telix Pharmaceuticals Stock
Telix Pharmaceuticals Debt→
Telix Pharmaceuticals Stock
Telix Pharmaceuticals Liabilities→
Telix Pharmaceuticals Stock
Telix Pharmaceuticals Equity→
Telix Pharmaceuticals Stock
Telix Pharmaceuticals AAQS→
Telix Pharmaceuticals Stock
Telix Pharmaceuticals Employees→
Telix Pharmaceuticals Stock
Telix Pharmaceuticals ROE→
Telix Pharmaceuticals Stock
Telix Pharmaceuticals ROA→
Telix Pharmaceuticals Stock
Telix Pharmaceuticals ROCE→
Telix Pharmaceuticals Stock
Telix Pharmaceuticals News→
Telix Pharmaceuticals Stock
Telix Pharmaceuticals Analyst Price Targets→